

REMARKS

Entry of this amendment is respectfully requested. Original claims 1-20 have been cancelled. No new matter is added by this amendment; the new claims are supported by the specification as originally filed.

New claims 21, 23, 29, 31, 37 and 39 are supported on page 5, lines 12-20.

New claims 22, 30 and 38 are supported at page 44, lines 30-32.

New claims 24, 32 and 40 are supported at page 46, lines 7-13.

New claims 25, 33 and 41 are supported at page 47, lines 1-12.

New claims 26, 34 and 42 are supported at page 51, line 16 to page 52, line 21.

New claims 27, 35 and 43 are supported at page 53, lines 22-25.

New claims 28, 36 and 44 are supported at page 50, lines 23-29.

The newly added claims are presented in response to the restriction requirement of March 31, 2003. Restriction among three species of antibodies (human, rat and mouse) was required. Consistent with that requirement claims 21-28 are drawn to human antibodies, claims 29-36 are drawn to rat antibodies and claims 37-44 are drawn to mouse antibodies. Applicants elect with traverse to prosecute claims 21-28 drawn to human antibodies. The traversal is on the grounds that all three groups should be found allowable without further search since each is claiming an antibody to a polypeptide already found patentable in parent application, U.S.S.N. 08/857,389, now U.S. Patent No. 6,479,642 B1.

The Examiner also suggested that correction was required on page 95 since SEQ ID NO:8 is referred to as both a rat and mouse sequence. This is in fact correct since the sequences of rat and mouse cortistatin-14 are identical. See Page 96, lines 1-5. Likewise, SEQ ID NOs 23 and 24 are identified at page 115, lines 9-12 as cortistatin analogs.

Application No.: 09/766,396
Amdt. dated April 30, 2003
Reply to Office Action of March 31, 2003
Page 7

PATENT

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



William Schmonsees
Reg. No. 31,796

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400 Fax: 415-576-0300
WS:bah

PA 3275684 v1